Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

HK Short Interest: Wuxi Biologics, HK China Gas, Geely, Netease

HK Short Interest: Galaxy Entertainment, JD.com, Alibaba, Baidu

HK Short Interest: Short Spiked for HKEx, Nongfu, Baidu

HK Short Interest: HSBC, Techtronic, SHK Properties, Kuaishou

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Quantitative Analysis

China Health care / Quantitative Analysis

<ul>
<li>We analyzed the latest HK SFC report for aggregate short position as of Mar 25. </li>
<li>Top short increases and decreases were tabulated for one week and four week period. </li>
<li>We highlight short interest increases for Wuxi Biologics and Hong Kong &amp; China Gas. </li>
</ul>


We analyzed the latest HK SFC report for aggregate short position as of Mar 25. 
Top short increases and decreases were tabulated for one week and four week period. 
We highlight short interest increases for Wuxi Biologics and Hong Kong &amp; China Gas. 


HK Short Interest: Wuxi Biologics, Kong Kong & China Gas